A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease



Status:Recruiting
Conditions:Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - Any
Updated:3/27/2019
Start Date:December 20, 2018
End Date:October 29, 2020
Contact:Study Contact
Email:JNJ.CT@sylogent.com
Phone:844-434-4210

Use our guide to learn which trials are right for you!

A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease

The primary purpose of this study is to evaluate the efficacy and safety of a single
intravenous (IV) re-induction dose of approximately 6 milligram per kilogram (mg/kg)
ustekinumab in participants with secondary loss of response (LoR) to subcutaneous (SC) every
8 Weeks (q8w) 90 mg ustekinumab maintenance therapy.

This study compares the efficacy and safety of a single weight-tiered based IV re-induction
dose of approximately 6 mg/kg ustekinumab versus continuing with regular SC q8w 90 mg
ustekinumab administration. It consists of screening (5 weeks); treatment period (Week 0 to
24); and safety follow up visit (20 weeks after last dose). The primary hypothesis is that a
single IV re-induction dose of ustekinumab is superior to continuing with regular SC q8w
maintenance treatment as measured by clinical response after 16 weeks of treatment. Study
assessments will include Crohn's disease activity index (CDAI), video ileocolonoscopy,
patient-reported outcomes (PROs), laboratory evaluations, biomarkers, review of concomitant
medications and adverse events (AEs), and evaluation of serum concentrations of study agent
as well as development of antibodies to study agent. All participants will be randomly
assigned to receive either ustekinumab IV re-induction or regular SC q8w 90 mg ustekinumab
injection at baseline in a double dummy design. No participants will be treated with placebo
only.

Inclusion criteria:

- A history of Crohn's disease or fistulizing Crohn's disease of at least 3 months'
duration, with colitis, ileitis, or ileocolitis, confirmed at any time in the past by
radiography, histology, and/or endoscopy

- Initially responded to ustekinumab induction therapy, administered according to the
local label, followed by secondary loss of response (LoR) to ustekinumab. Secondary
LoR to ustekinumab is defined as active disease at study baseline, proven by a Crohn's
Disease Activity Index (CDAI) score of greater than or equal to (>=) 220 and <=450
with at least one of the following: Elevated C-reactive protein (CRP) (>3.0 milligram
per liter [mg/L]); and/or elevated Fecal calprotectin (FeCa) >250 milligram per
kilogram [mg/kg]); and/or endoscopy (performed within the 3 months before baseline)
with evidence of active Crohn's disease during the current disease flare (that is
[i.e.], ulcerations in the ileum and/or colon)

- Participants receiving either oral 5-aminosalicylic acid (5-ASA) compounds, oral
corticosteroids (for example {e.g.}, prednisone, budesonide) at a
prednisone-equivalent dose of <=40 mg/day or <=9 mg/day of budesonide, antibiotics
used as the primary treatment of Crohn's disease, or conventional immunomodulators
(i.e., azathioprine [AZA], 6-mercaptopurine [6-MP], or methotrexate [MTX]) are
permitted providing the doses indicated are stable before baseline or have been
discontinued before baseline within the protocol defined durations

Exclusion Criteria:

- Complications of Crohn's disease, such as symptomatic strictures or stenoses, short
gut syndrome, or any other manifestation that might be anticipated to require surgery,
could preclude the use of the CDAI to assess response to therapy, or would possibly
confound the ability to assess the effect of treatment with ustekinumab

- Currently has or is suspected to have an abscess. Recent cutaneous and perianal
abscesses are not exclusionary if drained and adequately treated at least 3 weeks
before baseline (or 8 weeks before baseline for intra-abdominal abscesses) provided
there is no anticipated need for any further surgery. Participants with active
fistulas may be included if there is no anticipation of a need for surgery and there
are currently no abscesses identified

- Any kind of bowel resection within 6 months or any other intra-abdominal surgery
within 3 months before baseline

- A draining (i.e., functioning) stoma or ostomy

- Received any of the following prescribed medications or therapies within a specified
period including any off-label use of ustekinumab, additional IV re-induction or
shortened frequency of subcutaneous dose administration, after the initial
weight-tiered based IV induction dose of ustekinumab
We found this trial at
18
sites
Seattle, Washington 98104
(206) 543-2100
Univ of Washington Founded in 1861 by a private gift of 10 acres in what...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1211 Medical Center Dr
Nashville, Tennessee 37232
(615) 322-5000
Vanderbilt Univ Med Ctr Vanderbilt University Medical Center (VUMC) is a comprehensive healthcare facility dedicated...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
2 Stenglinstraße
Augsburg, 86156
?
mi
from
Augsburg,
Click here to add this to my saved trials
Chevy Chase, Maryland 20815
?
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Chicago, Illinois 60637
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Colorado Springs, Colorado 80907
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
?
mi
from
Hamden, CT
Click here to add this to my saved trials
6550 Fannin St
Houston, Texas 77030
(713) 790-3311
Houston Methodist Hospital Houston Methodist is comprised of a leading academic medical center in the...
?
mi
from
Houston, TX
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
New York, New York 10029
?
mi
from
New York, NY
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73112
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
601 E Rollins St
Orlando, Florida 32803
(407) 303-5600
Florida Hospital Florida Hospital is one of the country
?
mi
from
Orlando, FL
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Suwanee, GA
Click here to add this to my saved trials
Tampa, Florida 33613
?
mi
from
Tampa, FL
Click here to add this to my saved trials
?
mi
from
Webster, TX
Click here to add this to my saved trials